2BBBullish & Bearish
Agios Pharmaceuticals, Inc. (AGIO) trades on NASDAQ. It operates in the Health Care sector, Biotechnology industry. Its current 2BB score is 59 out of 100.
Agios Pharmaceuticals Inc. is a publicly trading American pharmaceutical company pioneering therapies for genetically defined diseases, with a near-term focus on developing therapies for hemolytic anemias. The company was founded in 2008 by Lewis Cantley, Tak Mak and Craig Thompson. Agios is a Delaware corporation headquartered in Cambridge, Massachusetts. The company tendered an initial public offering in July 2013.
Agios Pharmaceuticals, Inc.’s current 2BB score is 59 out of 100, built from the signal categories below.
| Signal | Score | Reading |
|---|---|---|
| Activity | 62 | High |
| Momentum | 76 | Improving |
| Financial strength | 44 | Normal |
| Quality | 100 | Very Strong |
| Risk | 42 | Moderate |
| Founded | 2008 |
| Employees | 540 |
| 52-week range | $22.24 – $46.00 |
| Report date | EPS actual | EPS estimate | Revenue actual | Revenue estimate |
|---|---|---|---|---|
| 2027-02-10 | — | -1.1053 | — | $64.42M |
| 2026-10-28 | — | -1.2387 | — | $54.83M |
| 2026-07-30 | — | -1.7013 | — | $26.04M |
| 2026-04-29 | -1.69 | -1.8367 | $20.75M | $13.92M |